The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ) that's also probably bad news for Hims & Hers Health ( HIMS -17.80%).

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

The FDA announced the end of the shortage of Novo Nordisk's drugs, Wegovy and Ozempic, which will impact sales of cheaper compounded versions. Compounded copies of Eli Lilly's drugs, Zepbound and ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...

The U.S. drug regulator declared that the shortage of weight-loss medications Wegovy and Ozempic has been resolved, Danish pharma giant Novo Nordisk said.

The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, ...

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...